Balanced news tone
News Sentiment
BLRX sentiment intelligence
BioLineRx Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-6.1% over one week, -8.2% over four weeks, trend active, and below fair value.
BioLineRx, Hemispherian to present GLIX1 ovarian cancer data at ESMO
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 11:00
- Source
- PR Newswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 11:00
- Source
- PR Newswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 23 Mar 2026 07:00
- Source
- PR Newswire
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 24 Nov 2025 08:00
- Source
- PR Newswire
Biolinerx (BLRX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:26
- Source
- Stock Titan
What is the current Price Target and Forecast for BioLineRx (BLRX)
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 16 Aug 2022 11:27
- Source
- Zacks Investment Research
Biolinerx Stock Price Forecast. Should You Buy BLRX?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 01 Dec 2020 17:10
- Source
- StockInvest.us